Compare GDDY & TEVA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | GDDY | TEVA |
|---|---|---|
| Founded | 1997 | 1901 |
| Country | United States | Israel |
| Employees | N/A | 32842 |
| Industry | EDP Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 12.5B | 36.7B |
| IPO Year | 2014 | N/A |
| Metric | GDDY | TEVA |
|---|---|---|
| Price | $86.24 | $29.02 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 17 | 8 |
| Target Price | ★ $142.00 | $37.38 |
| AVG Volume (30 Days) | 2.4M | ★ 6.3M |
| Earning Date | 04-30-2026 | 04-29-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 6.22 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $8.02 | N/A |
| Revenue Next Year | $6.08 | $2.51 |
| P/E Ratio | ★ $13.61 | $28.19 |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $73.06 | $12.47 |
| 52 Week High | $193.55 | $37.35 |
| Indicator | GDDY | TEVA |
|---|---|---|
| Relative Strength Index (RSI) | 44.92 | 33.65 |
| Support Level | $80.42 | $28.38 |
| Resistance Level | $93.65 | $31.99 |
| Average True Range (ATR) | 3.13 | 0.97 |
| MACD | 0.44 | -0.23 |
| Stochastic Oscillator | 39.96 | 11.38 |
GoDaddy Inc provides digital solutions and services for entrepreneurs, small businesses, individuals, organizations, developers, designers, and domain investors. It offers tools intended to support business creation and management through an integrated service platform. The company operates through two segments: Applications and Commerce (A&C) and Core Platform (Core). The majority of the company's revenue is derived from the Core Platform segment, which consists of sales of domain registrations and renewals, aftermarket domain sales, website hosting products and website security products. Geographically, it generates the maximum revenue from the United States.
Teva Pharmaceutical, based in Israel, is the leading generic drug manufacturer in the world. Teva derives half of its sales from North America and makes up a high-single-digit percentage of the total number of generic prescriptions in the US. It also has a significant presence in Europe, Japan, Russia, and Israel. Besides generics, Teva has a portfolio of innovative medicines and biosimilars in three main therapeutic areas: the central nervous system with Copaxone, Ajovy, and Austedo; respiratory with Qvar and ProAir; and oncology with Truxima, Herzuma, and Bendeka/Treanda. Teva also sells active pharmaceutical ingredients, offers contract manufacturing services, and owns Anda, a US-based generic and specialty drug distributor.